Factors That Predict Radiographic Progression of Ankylosing Spondylitis

No abstract available
Source: Lippincott's Bone and Joint Newsletter - Category: Orthopaedics Tags: CME Article Source Type: news

Related Links:

CONCLUSIONS: IgA antibodies against CD74 are not only markers of AS, but are associated with structural damage development in the sacroiliac joints and in the spine. PMID: 32242816 [PubMed - as supplied by publisher]
Source: Clinical and Experimental Rheumatology - Category: Rheumatology Tags: Clin Exp Rheumatol Source Type: research
ConclusionAlthough no significant protective effect of TNFi treatment on spinal radiographic progression was seen over the course of 2 years or ≥4 years in patients with axial SpA, our analysis restricted to studies with a low risk of bias showed a protective effect of TNFi after ≥4 years. Therefore, long‐term TNFi exposure might confer beneficial effects on spinal radiographic progression in axial SpA. No difference in radiographic p rogression at 2 years was seen in either the NSAID or secukinumab treatment groups compared to their controls. Future studies should explore the effects of biologic treatment on radio...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: Review Source Type: research
ConclusionThe IgG-Gal ratio was significantly increased in AS patients. In clinical care, it may be used as a potential biomarker for diagnosis in the future.Key Points• IgG galactosylation level was abnormal in SpA patients.• IgG galactosylation level was associated with MRI indices.
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
Nonsteroidal antiinflammatory drugs (NSAIDs) are the first ‐line pharmacotherapy for patients with axial spondyloarthritis (SpA). In recent years, treatment options have expanded with the availability of biologic agents, including tumor necrosis factor inhibitors and interleukin‐17 inhibitors. However, a treatment strategy that clearly prevents syndesmo phyte formation has not been established. Observational studies of patients with ankylosing spondylitis indicated potential disease‐modifying effects of NSAIDs, but two randomized trials came to different conclusions. More broadly, whether any of the currently availab...
Source: Arthritis and Rheumatology - Category: Rheumatology Authors: Tags: New Perspectives in Rheumatology Source Type: research
Publication date: Available online 17 February 2020Source: The Egyptian RheumatologistAuthor(s): Rehab A. Sallam, Amany S. ElbahnasawyAbstractAim of the workTo assess health-related quality of life (HRQoL) and associated variables in Egyptian ankylosing spondylitis (AS) patients.Patients and methods50 male patients with AS and 50 age-matched controls were enrolled. Clinical and laboratory data were examined including history for peripheral arthritis. Visual analog scale (VAS), Bath AS disease activity index (BASDAI), AS disease activity score (ASDAS)-C-reactive protein (CRP) and ASDAS-erythrocyte sedimentation rate (ESR), ...
Source: The Egyptian Rheumatologist - Category: Rheumatology Source Type: research
ConclusionsOur results showed that in real-life settings, patients improve in BASMI and BASFI. Furthermore, factors associated with this improvement were identified.
Source: Rheumatology and Therapy - Category: Rheumatology Source Type: research
ConclusionIsotretinoin-induced axial SpA is a prevalent side effect in acne vulgaris patients. Early detection and follow-up of isotretinoin-induced sacroiliitis can be facilitated by MRI. Cessation of isotretinoin resulted in complete resolution in all affected patients.Key Points•Detection of underdiagnosed isotretinoin side effects which are common but not always correctly diagnosed and managed.•Incidence, diagnosis, and management of these side effects in a real-world setting.• This is the first large prospective longitudinal cohort study to report on axial manifestations in patients treated with isotret...
Source: Clinical Rheumatology - Category: Rheumatology Source Type: research
This study is the first to evaluate the validity, reliability and feasibility of the ASPI in another patient population, including both radiographic- and non-radiographic axSpA patients. METHODS: AxSpA patients were recruited from Rheumatology clinics in Santiago, Chile. Dutch instructions were translated to Spanish via a forward-backward procedure. Study visits were performed at baseline and 1-4 weeks later. Four ASPI observers were involved, measuring the performance times of the three ASPI tests. Validity was assessed through a patient questionnaire (NRS 0-10: ≥6 'sufficient'). For reliability, intra class corre...
Source: J Rheumatol - Category: Rheumatology Authors: Tags: J Rheumatol Source Type: research
AbstractPurposeThe aim is to evaluate Achilles tendon enthesopathy with ultrasound (US) in ankylosing spondylitis (AS) and non ‐radiographic axial SpA (nr‐axSpA) patients and controls, and compare these groups in terms of associations between disease activity parameters and ultrasonographic Achilles enthesitis signs.MethodsA total of 24 AS and 20 nr ‐axSpA patients fulfilling the Assessment in Spondyloarthritis International Working Group criteria for axSpA and 30 controls were enrolled. Demographic characteristics, erythrocyte sedimentation rate, C‐reactive protein (CRP), human leukocyte antigen (HLA)‐B27, Bath ...
Source: International Journal of Rheumatic Diseases - Category: Rheumatology Authors: Tags: ORIGINAL ARTICLE Source Type: research
AbstractBackground and ObjectiveSecukinumab, an anti-interleukin (IL)-17A monoclonal antibody, has demonstrated low radiographic progression over 4  years in patients with ankylosing spondylitis (AS). An adalimumab (tumor necrosis factor [TNF] inhibitor) biosimilar, GP2017 (SDZ-ADL; Sandoz), has been approved by the European Medicines Agency (July 2018) for use in all same indications as adalimumab, including AS. Adalimumab has also shown low long-term radiographic progression in patients with AS. Direct comparison of radiographic progression in AS between IL-17A and TNF inhibitors has not been studied. SURPASS is the...
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Ankylosing Spondylitis | Orthopaedics | Radiography